We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$4.62B
AUM Growth
Cap. Flow
+$4.56B
Cap. Flow %
98.7%
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$400M
2
AAPL icon
Apple
AAPL
+$352M
3
MSFT icon
Microsoft
MSFT
+$326M
4
AMZN icon
Amazon
AMZN
+$218M
5
META icon
Meta Platforms (Facebook)
META
+$195M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Technology 45.41%
2 Consumer Discretionary 17.29%
3 Communication Services 14.35%
4 Healthcare 6.6%
5 Consumer Staples 4.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BEAM icon
401
Beam Therapeutics
BEAM
$2.68B
$43.1K ﹤0.01%
+1,739
New +$44.4K
APGE icon
402
Apogee Therapeutics
APGE
$10.1B
$42.8K ﹤0.01%
+945
New +$48.2K
LGND icon
403
Ligand Pharmaceuticals
LGND
$5.77B
$42.5K ﹤0.01%
+397
New +$44.9K
IVT icon
404
InvenTrust Properties
IVT
$2.79B
$42.2K ﹤0.01%
+1,402
New +$42.2K
SUPN icon
405
Supernus Pharmaceuticals
SUPN
$2.7B
$41.9K ﹤0.01%
+1,159
New +$40.8K
MIRM icon
406
Mirum Pharmaceuticals
MIRM
$6.56B
$41.7K ﹤0.01%
+1,008
New +$42K
SHO icon
407
Sunstone Hotel Investors
SHO
$2.19B
$41.6K ﹤0.01%
+3,510
New +$38.3K
HRMY icon
408
Harmony Biosciences
HRMY
$2.08B
$41.2K ﹤0.01%
+1,198
New +$41.2K
MPT
409
Medical Properties Trust
MPT
$2.84B
$40.9K ﹤0.01%
+10,361
New +$46.4K
AKRO
410
DELISTED
Akero Therapeutics
AKRO
$40.8K ﹤0.01%
+1,466
New +$44.4K
CGON icon
411
CG Oncology
CGON
$6.1B
$40.7K ﹤0.01%
+1,420
New +$48.6K
ROIC
412
DELISTED
Retail Opportunity Investments Corp.
ROIC
$40.2K ﹤0.01%
+2,316
New +$38.7K
CURB
413
Curbline Properties
CURB
$3.53B
$39.8K ﹤0.01%
+1,715
New +$40.3K
IRON icon
414
Disc Medicine
IRON
$2.81B
$39.6K ﹤0.01%
+625
New +$36.2K
WVE icon
415
Wave Life Sciences
WVE
$1.12B
$39.6K ﹤0.01%
+3,202
New +$42.7K
AGIO icon
416
Agios Pharmaceuticals
AGIO
$2.08B
$39.3K ﹤0.01%
+1,197
New +$56.2K
AMPH icon
417
Amphastar Pharmaceuticals
AMPH
$907M
$37.5K ﹤0.01%
+1,010
New +$46.2K
IBRX icon
418
ImmunityBio
IBRX
$7.15B
$37.5K ﹤0.01%
+14,632
New +$61K
MNKD icon
419
MannKind Corp
MNKD
$1.19B
$37.2K ﹤0.01%
+5,791
New +$38.8K
NMRA icon
420
Neumora Therapeutics
NMRA
$306M
$36K ﹤0.01%
+3,392
New +$40.7K
INDV icon
421
Indivior Pharmaceuticals
INDV
$4.74B
$35.6K ﹤0.01%
+2,862
New +$29.4K
DVAX
422
DELISTED
Dynavax Technologies
DVAX
$35.2K ﹤0.01%
+2,760
New +$33.4K
FTRE icon
423
Fortrea Holdings
FTRE
$1.93B
$35.1K ﹤0.01%
+1,883
New +$36.7K
IIPR icon
424
Innovative Industrial Properties
IIPR
$1.77B
$34.3K ﹤0.01%
+515
New +$58K
ARQT icon
425
Arcutis Biotherapeutics
ARQT
$3.48B
$34.2K ﹤0.01%
+2,458
New +$26.9K

Similar funds

GF Fund Management's Q4 2024 Portfolio in Review

Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.

Its largest position is NVIDIA: 2,904,119 shares worth $390M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.

  • GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
  • GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
  • GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.

Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.